Clinical Endoscopy

The Korean Society of Gastrointestinal Endoscopy (대한소화기내시경학회)
권호 표지
DOI QR코드

DOI QR Code

Long-term follow-up of patients developing gastric mucosal lesions after initiating the potassium-competitive acid blocker vonoprazan

  • Kimitoshi Kubo (Department of Gastroenterology, National Hospital Organization Hakodate National Hospital) ;
  • Noriko Kimura (Department of Pathology, National Hospital Organization Hakodate National Hospital)
  • Received : 2023.07.20
  • Accepted : 2023.08.05
  • Published : 2024.07.30
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem 2012; 55:4446-4456. https://doi.org/10.1021/jm300318t
  2. Parsons ME, Keeling DJ. Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs 2005;14:411-421. https://doi.org/10.1517/13543784.14.4.411
  3. Matsukawa J, Kogame A, Tagawa Y, et al. Radiographic localization study of a novel potassium-competitive acid blocker, vonoprazan, in the rat gastric mucosa. Dig Dis Sci 2016;61:1888-1894. https://doi.org/10.1007/s10620-016-4100-y
  4. Miyamoto S, Matsuno Y, Kato M, et al. Parietal cell protrusions and dilated oxyntic glands from use of vonoprazan. Am J Gastroenterol 2017;112:1899-1901. https://doi.org/10.1038/ajg.2017.364
  5. Kubo K, Kimura N, Matsuda S, et al. Vonoprazan-associated gastric mucosal redness: a report of four cases. Intern Med 2020;59:507-511. https://doi.org/10.2169/internalmedicine.3715-19
  6. Kubo K, Kimura N, Watanabe R, et al. Vonoprazan-associated gastric mucosal redness in non-Helicobacter pylori-infected and Helicobacter pylori-eradicated stomach. Case Rep Gastroenterol 2021;15:751-758. https://doi.org/10.1159/000518292
  7. Nishiyama N, Kobara H, Ayaki M, et al. White spot, a novel endoscopic finding, may be associated with acid-suppressing agents and hypergastrinemia. J Clin Med 2021;10:2625.
  8. Yoshizaki T, Morisawa T, Fujinami M, et al. Propensity score matching analysis: incidence and risk factors for "stardust" gastric mucosa, a novel gastric finding potentially induced by vonoprazan. Aliment Pharmacol Ther 2021;53:94-102. https://doi.org/10.1111/apt.16151
  9. Iwamuro M, Shiraha H, Okada H. Gastric polyps' regression after potassium-competitive acid blocker cessation. J Gen Fam Med 2022;23:358-359. https://doi.org/10.1002/jgf2.552
  10. Goto C, Okimoto K, Matsusaka K, et al. Long-term vonoprazan administration causes gastric fundic gland-type hyperplastic polyps and chronic bleeding. Clin J Gastroenterol 2023;16:159-163. https://doi.org/10.1007/s12328-022-01751-0